-
(单词翻译:双击或拖选)
By Jane M Friedman
Washington, DC
20 April 2006
watch Biotech Industry report
A report by the consulting firm Ernst and Young says that, although huge pharmaceutical1 firms like Merck and Pfizer pour billions into research, small biotechnology companies are responsible for most of the new drugs approved in the U.S. last year.
------------------------------------------
Pharmaceutical giants, like Merck and Pfizer, profiting from hundreds of medications and over-the-counter treatments, spend more than $60 billion a year on research and commercials. But smaller biotech firms outstripped2 the giants in 2005 with 18 new drugs approved for market, out of a total 29.
James Greenwood
James Greenwood is president of the Biotechnology Industry Organization. "The little biotech companies are entrepreneurial. They're risk takers, they will go looking for a brand new molecule3 to cure a disease that's not been tackled before. Big pharmaceutical companies have such huge sales forces, such huge infrastructure4, that they have to limit their risk taking. They're always looking for a tweak to an existing drug that enables them to get some great volume of sales."
But spokesmen for the pharmaceuticals5 say they are taking big risks to research new treatments for widespread and even rare diseases.
Biotech companies, more than 1,000 of them, are using new discoveries in DNA6, genetics and cell biology to better understand how the body works in order to combat and prevent disease.
Last year, one biotech firm developed Insulin that's inhaled7, not injected. It hits the market soon.
MedImmune, which developed a flu vaccine8 in a nasal spray, is working on a spray to protect against the deadly strain of avian flu, which officials say could become a pandemic.
EntreMed, outside Washington D.C., is developing a new drug that relies on an understanding of how blood vessels9 help tumors grow and how cutting the blood supply to tumors can kill them.
But though biotechs are doing groundbreaking work, their finances are precarious10. Many are funded, at first, by venture capitalists. Drug development can take up to 10 years. And the industry has lost billions of dollars since the first biotech was founded 30 years ago.
Some of the publicly traded firms have seen their stock prices collapse11 when clinical trials have failed.
"The biggest challenge for biotech companies these days is the early stage financing," says Greenwood.
One way to get that financing is in partnerships12 with the pharmaceuticals. Biotech companies say if they can stay afloat, they will bring unique ways to improve health worldwide.
1 pharmaceutical | |
adj.药学的,药物的;药用的,药剂师的 | |
参考例句: |
|
|
2 outstripped | |
v.做得比…更好,(在赛跑等中)超过( outstrip的过去式和过去分词 ) | |
参考例句: |
|
|
3 molecule | |
n.分子,克分子 | |
参考例句: |
|
|
4 infrastructure | |
n.下部构造,下部组织,基础结构,基础设施 | |
参考例句: |
|
|
5 pharmaceuticals | |
n.医药品;药物( pharmaceutical的名词复数 ) | |
参考例句: |
|
|
6 DNA | |
(缩)deoxyribonucleic acid 脱氧核糖核酸 | |
参考例句: |
|
|
7 inhaled | |
v.吸入( inhale的过去式和过去分词 ) | |
参考例句: |
|
|
8 vaccine | |
n.牛痘苗,疫苗;adj.牛痘的,疫苗的 | |
参考例句: |
|
|
9 vessels | |
n.血管( vessel的名词复数 );船;容器;(具有特殊品质或接受特殊品质的)人 | |
参考例句: |
|
|
10 precarious | |
adj.不安定的,靠不住的;根据不足的 | |
参考例句: |
|
|
11 collapse | |
vi.累倒;昏倒;倒塌;塌陷 | |
参考例句: |
|
|
12 partnerships | |
n.伙伴关系( partnership的名词复数 );合伙人身份;合作关系 | |
参考例句: |
|
|